# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001213900-25-045090
Filing Date
2025-05-19
Accepted
2025-05-19 08:02:13
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE ADDITIONAL MATERIALS | ea0241493-02.htm | DEFA14A | 33717
2 | GRAPHIC | tproxy_001.jpg | GRAPHIC | 1357449
3 | GRAPHIC | tproxy_002.jpg | GRAPHIC | 1380135
| Complete submission text file | 0001213900-25-045090.txt |  | 3805879

Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

EIN.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39138 | Film No.: 25961544
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)